Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, February 28, 2019
WuXi Biologics congratulates its strategic partner Amicus Therapeutics on receiving FDA Breakthrough Therapy Designation for AT-GAA (ATB200/AT2221).
read more
WuXi Biologics and Immune Pharmaceuticals announced a development and manufacturing agreement for the production of bertilimumab, Immune's first-in-class anti-eotaxin-1 monoclonal antibody.
read more
Thursday, January 16, 2020
WuXi Biologics and Almirall announced the signing of a strategic collaboration agreement enabling Almirall to leverage the proprietary WuXiBody™ platform to develop bispecific antibodies for dermatological diseases.
read more
Thursday, August 01, 2024
WuXi Biologics announced that four manufacturing facilities and Suzhou Biosafety Testing Center in China have received Good Manufacturing Practice (GMP) certificates from the European Medicines Agency (EMA), demonstrating the company's commitment to ...
read more
Wednesday, March 21, 2018
WuXi Biologics has selected 4,000 liter (L) Custom Single Run (CSR) disposable bioreactors from ABEC for its new commercial manufacturing facility (MFG4) in Wuxi city, Jiangsu, China.
read more
Wednesday, January 31, 2024
WuXi Biologics announced the successful completion of the first manufacturing run at its drug substance facility MFG7, paving the way for large-scale commercial manufacturing projects at this Ireland site.
read more
WuXi Biologics has entered into a strategic partnership LOI with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market.
read more
Friday, February 14, 2020
WuXi Biologics has released the following statement addressing the Coronavirus outbreak.
read more
Wednesday, February 09, 2022
We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries in Shanghai and Wuxi will be added to the department's "Unverified List" (UVL) on February 8, 2022.
read more
WuXi Biologics has received EMA GMP certificates for the production of Trogarzo™ at its cGMP DS and DP manufacturing facilities in Wuxi city and its cGMP cell banking facilities in Shanghai.
read more
Thursday, February 27, 2025
WuXi Biologics announced that it has again passed the GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities (MFG2 and MFG5), in Wuxi city.
read more
WuXi Biologics announced the launch of WuXiHigh™2.0, a high-throughput formulation development platform designed for high concentration biologics. The platform enables protein concentrations of up to 230 mg/mL and achieves viscosity reduction by up ...
read more
Tuesday, October 17, 2023
WuXi Biologics has launched a new proprietary bioprocessing platform WuXiUI™, an ultra-intensified, fed-batch solution that enhances the productivity and quality of multiple different CHO or other mammalian cell lines and product modalities.
read more
Monday, November 01, 2021
WuXi Biologics a global company with leading open-access biologics technology platforms, announced it has successfully launched the GMP operation of its new drug product facility located in Wuxi, China, which is the eighth operational drug product ...
read more
Tuesday, December 02, 2025
WuXi Biologics announced that it has signed a strategic Memorandum of Understanding (MoU) with the Qatar Free Zones Authority (QFZ) to extend WuXi Biologics' global network and capabilities to the Middle East.
read more